11.07.22 -- eConsent For Complex Trial Designs And Therapeutic Areas

Master protocol design trials require an endless stream of consent forms, adding time, cost, and risk to each study. A feature-rich electronic consent platform can simplify those processes and improve patient engagement along the way.

Many pharmaceutical companies have become increasingly frustrated with the paper consent form process and the undue burden it placed on patients. Scott Askin explains why Novartis, determined to improve the patient experience, has begun to deploy eConsent and what they’ve learned along the way.

Electronic informed consent (eConsent) platforms are among the most advantageous clinical technology products that sponsors and sites can add to their operations. Why then are many sites and sponsors still wary of giving up their paper-based past?

Protocol amendments are inevitable, and unfortunately, they are one of the greatest sources of deviations in a trial. Every time an amendment occurs, each clinical trial participant must consent to the change. Learn how deploying electronic consent has provided measurable benefits in diverse trial types around the world.